Intervention: ASPIRIN
Trial phase: Phase 2
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: 2.0 mg dose, intranasal powder, single spray, administered once
Eligibility criteria:
Inclusion Criteria:

Patients with histologically and/or cytologically confirmed cancer
ECOG performance status of 0, 1, or 2
Patients with life expectancy of at least 3 months
Patients who are chemotherapy naïve
Patients who will be receiving the first cycle of a highly emetogenic regimen according to the MASCC criteria or the Hesketh criteria
Patients with adequate metabolic or hematologic values for chemotherapy
Patients with intact nasal mucosa
Non child-bearing potential patients
Patients able to read and write at a competent level, and capable of giving legal consent
Patients who have provided written informed consent

Exclusion Criteria:

Patients who do not receive a chemotherapy regimen which is a highly emetogenic chemotherapy regimen according to the MASCC or the Hesketh criteria
Patients with nasal cancers, pharyngeal cancers, maxillary sinus cancers, or ethmoid sinus cancers
Patients with nasal ulcers, septal perforation, or other nasal conditions that may interfere with IN administration
Patients with any episode of retching, vomiting, or uncontrolled nausea within 48 hours before dosing with TRG and/or administration of chemotherapy
Patients who have received radiation therapy in the 14 days before dosing with TRG, or for whom radiation therapy is scheduled during the 7 days after a TRG dose
Patients who have received any investigational product within 30 days prior to study entry
Patients who have received any drug or who were scheduled to receive any drug with antiemetic efficacy within 24 hours of the start of treatment
Patients who have an allergy or hypersensitivity to granisetron or other selective 5hydroxytryptamine3(5-HT3) receptor antagonists
Patients with ECOG performance status of 3 or 4
Patients who have or have a history of brain tumors, head cancers, or neck cancers
Patients who have a psychological problem that, in the Investigator's opinion, is severe enough to interfere with study eligibility or with interpretation of study results
Patients who are pregnant (urine test) or breastfeeding
Patients who have received prior cytotoxic chemotherapy given for the treatment of cancer
Patients scheduled to receive multiple day chemotherapy
Patients with clinically relevant abnormal laboratory values at the discretion of the Investigator
Patients with clinically relevant hepatic, renal, infectious, neurological, or psychiatric disorders, or any other major systemic illness at the discretion of the Investigator
Patients with any prevalence or cause of nausea and vomiting other than chemotherapy
Patients using systemic steroids for any indication, or patients using steroids other than dexamethasone for prevention of chemotherapy-induced nausea and vomiting, or patients using dexamethasone for chemotherapy-induced nausea and vomiting at doses other than recommended in the MASCC antiemetic guidelines
Patients with a QT interval greater than 500 ms or with acute ischemic changes or cardiac abnormality predisposing to arrhythmia on screening electrocardiogram (ECG) or by history
Patients with a history of drug and/or alcohol abuse.